Cervical cancer and prevention by vaccination: Results from recent trials

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Tjalma, W A A ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE; WART VIRUS VACCINE 16;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE GENITAL TRACT INFECTION; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; WART VIRUS;

FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 33749595944     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl263     Document Type: Article

References (16)

1. Tjalma WA, Van Waes TR, Van den Eeden LE, Bogers JJ. Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract Res Glin Obstet Gynaecol 2005; 19: 469-483.
2. Tjalma WA, Arbyn M, Paavonen J et al. Prophylactic human papillomavirus vaccines: The beginning of the end of cervical cancer. Int J Gynecol Cancer 2004; 14: 751-761.
3. Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285.
4. Tjalma WA, Weyler JJ, Bogers JJ et al. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001; 97: 223-230.
5. Trinh XB, Bogers JJ, Van Marck EA, Tjalma WA. Treatment policy of neuroendocrine small cell cancer of the cervix. Eur J Gynaecol Oncol 2004; 25: 40-44.
6. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
7. Mao C, Koutsky LA, Ault KA et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.
8. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364: 1757-1765.
9. Harper DM, Franco EL, Wheeler C et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus type 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
10. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
11. Villa LL, Costa RL, Petta CA et al. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) types 6, 11, 16, and 18 L1 virus-like particle (VLP) vaccine through up to 5 years follow-up. Presented at the European Research Organization on Genital Infection and Neoplasia, Paris, France. 26 April 2006.
12. Sattler C for the FUTURE I investigators. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, 19 December 2005.
13. Skjeldestad FE for the FUTURE II investigators. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithellal neoplasia (CIN) 2/3 risk. Presented at: Infectious Disease Society of America 43rd Annual Meeting, San Francisco, California, USA, 7 October 2005.
14. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27.
15. Pratt D, Goldenthal K, Gerber A. Preventative human papillomavirus (HPV) vaccines: Regulatory briefing document on endpoints. Vaccines and Related Biological Products Advisory Committee Meeting, 28-29 November 2001. Available at http://www.fda.gov/ohrms/docketst/ac/01/briefing/ 3805b1_01.htm.
16. Tjalma WA, Van Damme P. Is the public enough aware to accept a vaccination program against human papillomavirus? Vaccine 2005; 23: 3231.